Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genfleet Therapeutics (Shanghai) Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years
Newly diagnosed, pathologically (histologically or cytologically) confirmed, locally advanced, unresectable stage III NSCLC
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Measurable disease (according to RECIST v1.1 criteria)
Life expectancy \> 6 months
You may not be if
Has small cell lung cancer (SCLC) or tumors with the presence of small cell elements.
Has received prior treatment (chemotherapy, targeted therapy, or radiotherapy) for Stage III NSCLC
Prior exposure to immune-mediated therapy, including but not limited to, TGFβ inhibitors, anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies.
Known allergy or hypersensitivity to any of the IPs or any of the IP excipients.
Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving ≥20 Gy in total (V20) of more than 35% of lung volume.
Clareo Health | A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
